Charles Elliott Sigal Insider Profile

4 Followers
Charles Elliott Sigal, Director at Adaptimmune Therapeutics, holds 33.81K shares in Vir Biotechnology (Ticker: VIR), holds 0.00 shares in Surface Oncology (Ticker: SURF), holds 307.04K shares in Adaptimmune Therapeutics (Ticker: ADAP).
tipranks
Charles Elliott Sigal

Charles Elliott Sigal
Adaptimmune Therapeutics (ADAP)
Director

Ranked #79,399 out of 99,218 Corporate Insiders

Profitable Transactions

0%
0 out of 2 Profitable Transactions

Average Return

-42.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$569K
57.04%
42.96%
0.00%
A breakdown of Charles Elliott Sigal's holdings

Insider Roles

Vir Biotechnology
(VIR)
Director
Adaptimmune Therapeutics
(ADAP)
Director
Alnylam Pharma
(ALNY)
Director
Roles that Charles Elliott Sigal holds in companies

Most Profitable Insider Trade

Stock:
Adaptimmune Therapeutics
(ADAP)
Rating:Informative Buy
Date:May 18, 2016 - May 18, 2017
Return:-41.90%
The most profitable trade made by Charles Elliott Sigal

Charles Elliott Sigal's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Adaptimmune Therapeutics
May 19, 2016
Director
Informative Buy
23.40K
$244.40K
SURF
Surface Oncology
Sep 08, 2023
Uninformative Sell
$0.00
Vir Biotechnology
Jun 03, 2024
Director
Uninformative Buy
$324.54K
Alnylam Pharma
Director
List of latest transactions for each holding click on a transaction to see Charles Elliott Sigal's performance on stock

Charles Elliott Sigal insider profile FAQ

What is the percentage of profitable transactions made by Charles Elliott Sigal?
The percentage of profitable transactions made by Charles Elliott Sigal is 0%.
    What is the average return per transaction made by Charles Elliott Sigal?
    The average return per transaction made by Charles Elliott Sigal is -42.70%.
      What stocks does Charles Elliott Sigal hold?
      Charles Elliott Sigal holds: ADAP, SURF, VIR, ALNY stocks.
        What was Charles Elliott Sigal’s latest transaction?
        Charles Elliott Sigal latest transaction was an Uninformative Buy of ―.
          What was Charles Elliott Sigal's most profitable transaction?
          Charles Elliott Sigal’s most profitable transaction was an Informative Buy of ADAP stock on May 18, 2016. The return on the trade was -41.90%.
            What is Charles Elliott Sigal's role in Adaptimmune Therapeutics?
            Charles Elliott Sigal's role in Adaptimmune Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.